NEW YORK, April 05, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it has priced its upsized underwritten public offering of 2,343,750 shares of its common stock at a price to the public of $64.00 per share. In addition, in connection with the public offering, Intercept has granted to the underwriters a 30-day option to purchase up to an additional 351,563 shares of its common stock at the same price as the initial shares sold to the underwriters.
Intercept’s Chief Executive Officer and certain members of Intercept’s board of directors participated in the public offering at the price offered to the public and on the same terms as the other purchasers in the public offering.
Concurrent with the public offering, Intercept will sell, subject to the consummation of the public offering and other customary conditions, in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), 1,562,500 shares of its common stock to Intercept’s largest existing stockholder, Genextra S.p.A., Samsara BioCapital, L.P. and certain other purchasers at a sale price equal to the price to the public in the public offering. However, the consummation of the public offering is not contingent on the consummation of this concurrent private placement.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept now has operations in the United States, Europe and Canada.

